(Q34591203)

3 August 2017

title

Dystrophin quantification: Biological and translational research implications (English)

1 reference

Virginia Arechavala-Gomeza

3 August 2017

author

2

Virginia Arechavala-Gomeza

0 references

Volker Straub

16

Volker Straub

1 reference

3 August 2017

Karen Anthony

1

0 references

Kevin M. Flanigan

Kevin M Flanigan

20

0 references

Gisèle Bonne

Gisèle Bonne

9

0 references

Lucy Feng

7

Lucy Feng

1 reference

3 August 2017

6

Silvia Torelli

1 reference

3 August 2017

18

Caroline A Sewry

1 reference

3 August 2017

21

Francesco Muntoni

1 reference

3 August 2017

8

Narinder Janghra

1 reference

3 August 2017

11

Rita Barresi

1 reference

3 August 2017

Laura E Taylor

3

1 reference

3 August 2017

Adeline Vulin

4

1 reference

3 August 2017

Yuuki Kaminoh

5

1 reference

3 August 2017

Maud Beuvin

10

1 reference

3 August 2017

Matt Henderson

12

1 reference

3 August 2017

Steven Laval

13

1 reference

3 August 2017

Afrodite Lourbakos

14

1 reference

3 August 2017

Giles Campion

15

1 reference

3 August 2017

Thomas Voit

17

1 reference

3 August 2017

Jennifer E Morgan

19

1 reference

3 August 2017

language of work or name

English

0 references

publication date

29 October 2014

1 reference

3 August 2017

1 reference

3 August 2017

volume

83

1 reference

3 August 2017

issue

22

1 reference

3 August 2017

page(s)

2062-2069

1 reference

A sensitive, reproducible and objective immunofluorescence analysis method of dystrophin in individual fibers in samples from patients with duchenne muscular dystrophy

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

The ZZ domain of dystrophin in DMD: making sense of missense mutations.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Accurate Quantitation of Dystrophin Protein in Human Skeletal Muscle Using Mass Spectrometry

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

The carboxy-terminal third of dystrophin enhances actin binding activity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Internal deletion compromises the stability of dystrophin

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Systemic administration of PRO051 in Duchenne's muscular dystrophy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

PTC124 targets genetic disorders caused by nonsense mutations

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Dystrophin, its interactions with other proteins, and implications for muscular dystrophy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Dystrophin and mutations: one gene, several proteins, multiple phenotypes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Statistical methods for assessing agreement between two methods of clinical measurement

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Eteplirsen for the treatment of Duchenne muscular dystrophy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Quantification of dystrophin immunofluorescence in dystrophinopathy muscle specimens

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Dystrophin immunity in Duchenne's muscular dystrophy.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Effect of dystrophin gene deletions on mRNA levels and processing in Duchenne and Becker muscular dystrophies

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: Implication for clinical trials

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Measuring dystrophin—faster is not necessarily better

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression

9 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

Generation and Characterization of Transgenic Mice with the Full-length HumanDMDGene

9 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248450

The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009

9 December 2018

1 reference

12 December 2020

The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities

1 reference

12 December 2020

The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history

1 reference

12 December 2020

Best Practice Guidelines on molecular diagnostics in Duchenne/Becker muscular dystrophies

1 reference

12 December 2020

10.1212/WNL.0000000000001025

Identifiers

DOI

1 reference

3 August 2017

1 reference

3 August 2017

1 reference